FIELD: medicine.
SUBSTANCE: alloxan is introduced into rat's peritoneum in a dose of 15.0 mg/100 g of weight. Then, 6.5 weeks after alloxan has been introduced, and experimental diabetes has been developed, insulin-like growth factor 1 (IGF-1) 1 mcl is introduced into the vitreous body from an intravitreous approach.
EFFECT: method simplifies and reduces the length of formation of persistent primary macular oedema specific for diabetes mellitus, enables analysing the course of the pathological process, forming the new therapeutic regimens.
1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR SIMULATING DIABETIC MACULAR NEOVASCULARISATION | 2012 |
|
RU2504844C1 |
| USE OF CABERGOLINE IN TREATING PATHOLOGICAL CONDITIONS CAUSED BY HIGH LEVELS OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR | 2016 |
|
RU2698728C1 |
| METHOD FOR AGE-RELATED MACULAR DEGENERATION MODELING USING PHOTOTOXIC EFFECT | 2020 |
|
RU2727872C1 |
| METHOD FOR SIMULATING AGE-RELATED MACULAR DEGENERATION | 2011 |
|
RU2480844C1 |
| METHOD OF SIMULATING AN INFECTED WOUND IN RATS WITH BACKGROUND OF LONG-TERM CURRENT DIABETES MELLITUS | 2020 |
|
RU2735708C1 |
| METHOD FOR SIMULATING ALLOXAN DIABETES | 2013 |
|
RU2534411C1 |
| METHOD OF MODELLING ACUTE PANCREATITIS IN EXPERIMENT | 2008 |
|
RU2372668C1 |
| METHOD FOR TREATING NEPHROANGIOPATHY COMBINED WITH ALLOXAN DIABETES IN EXPERIMENTAL ANIMALS | 2008 |
|
RU2372898C1 |
| METHOD OF SURGICAL TREATMENT OF MACULAR EDEMA, COMPLICATED BY EPIRETINAL MEMBRANE IN DIABETES MELLITUS | 2018 |
|
RU2687592C1 |
| METHOD FOR CREATING TRANSLATIONAL MODEL OF DIABETIC PHENOTYPE OF CHRONIC HEART FAILURE | 2023 |
|
RU2817822C1 |
